Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (362)
Quality standard (29)
Guidance programme
Guidance programme
HealthTech guidance (20)
Technology appraisal guidance (342)
Apply filters
Showing 201 to 225 of 391
Guidance and quality standards awaiting development
Title
Type
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]
Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]
Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]
Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]
Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]
Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]
Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]
Technology appraisal guidance
Olezarsen for treating severe hypertriglyceridaemia [TSID12387]
Technology appraisal guidance
Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [TSID12376]
Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [TSID12375]
Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]
Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]
Technology appraisal guidance
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]
Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Technology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]
Technology appraisal guidance
Pain management (young people and adults)
Quality standard
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Technology appraisal guidance
Pancreatitis (including acute pancreatitis)
Quality standard
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]
Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
Technology appraisal guidance
Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]
Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]
Technology appraisal guidance
Pelvic floor dysfunction
Quality standard
Previous page
1
…
7
8
Current page
9
10
11
…
16
Page
9
of
16
Next page
Results per page
10
25
50
All
Back to top